Pharmaceutical Companies
- 420.980
- -2.585-0.61%
Youzhiyou Bio-B, from Wuhan, Hubei, was successfully listed in Hong Kong
On September 25, 2023, Wuhan Youzhiyou Biopharma Co., Ltd. (hereinafter referred to as “Youzhiyou Biotech”) (02496.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
Yiming Angke, successfully listed in Hong Kong, co-sponsor by Morgan Stanley and CICC
On September 5, 2023, Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“Yiming Angke” for short) (01541.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
Kintor Pharmaceutical shares soared more than 11%
Kintor Pharmaceutical shares soared 17.51%
Kintor Pharmaceutical shares surged 147% on news of Covid-19 drug efficacy
Deqi Medicine will present five abstract wall posters at the annual meeting of the American Association for Cancer Research in 2022
Five abstracts were selected for 2022 AACR. These wall posters will introduce the progress of the company's early clinical and preclinical pipeline. The types of pipelines involved include ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. March 9, 2022 / PRNewswire /-- leading innovative biopharmaceutical company Deqi Pharmaceutical Co., Ltd. ("Deqi Pharmaceuticals", HKSE: 6996.HK), a leading innovative biopharmaceutical company in the commercial stage of R & D, production and sale of the first and / or best blood and solid tumor therapy of its kind.
Deqi Pharmaceutical Announces ATG-101 's Phase I Clinical trial Application approved in China
March 10, 2022 / PRNewswire /-- Deqi Pharmaceutical Co., Ltd. ("Deqi Pharmaceuticals", HKSE: 6996.HK), a leading commercial innovative biopharmaceutical company dedicated to the research, production and sale of the first and / or best-of-class blood and solid tumor therapy, announced today The State Drug Administration of China (NMPA) has formally approved the phase I clinical trial (PROBE-CN) of ATG-101 for the treatment of advanced or metastatic solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL). ATG-
Lepu Biology officially landed on the Hong Kong Stock Exchange to focus on the field of tumor treatment.
02157.HK is officially listed on the Hong Kong Stock Exchange at HK $7.13 per share. Weiwu Capital (managed by Vivo Capital LLC), the cornerstone investor attracted by Lepu Biology's IPO, is the top fund in the global biomedical field. Another cornerstone investor, King Star, actually controls Lin Xianghong as a senior investor in the venture capital circle and has a wealth of successful investment experience in the industry. As cornerstone investors, Weiwu Capital and Lin Xianghong show that they are optimistic about the future development of Lepu Biology. It is understood that Lepu Biology on January 19, 2018
MicroPort MedBot's Vascular Intervention Robot Completes First Clinical Trial Surgery in China
Clover Bio's COVID Vaccine Candidate to Begin Phase 2 Clinical Trial as Booster Dose
MicroPort MedBot Launches Clinical Trial in China of Surgical Robot
Alphamab Oncology Gets Nod to Start China Phase 3 Study of Combination Therapy for Pancreatic Cancer
TOT Biopharm International Forms Pharma Sales JV With China Resources Pharmaceutical
European Commission Grants Orphan Drug Designation to Ascentage Pharma's Leukemia Treatment
CARsgen Therapeutics Gets Greenlight to Start Immunotherapy's Clinical Trials in Canada
CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater China
Ascletis Pharma Doses First Subject in US Study of Combination Therapy for Liver Disease
Ascletis Pharma Says Hepatitis Drug Study Data Included Among Best Research in Medical Conference
Ascletis Pharma Wins Nod to Start Hepatobiliary Disease Drug's Phase 2, 3 Studies in China for New Indication
CARsgen's Cell Therapy Admitted to EU Priority Medicines Program; Shares Jump 6%